Literature DB >> 7572046

Neurologic manifestations of intravascular lymphomatosis.

J E Chapin1, L E Davis, M Kornfeld, R N Mandler.   

Abstract

Intravascular lymphomatosis is a rare fatal neoplasm characterized by malignant cells of lymphocytic lineage producing vascular occlusions. The cerebral vasculature is particularly affected. Two patients seen at our institution presented with progressive neurologic deficits including dementia, hemiparesis and myelopathy. Review of an additional 64 reported cases with neurologic involvement indicates that patients developed intermittent fevers, an encephalopathy ranging from acute disorientation to rapidly progressive dementia, and focal signs such as hemiparesis and myelopathy. Common laboratory abnormalities include elevated cerebrospinal fluid protein and a lymphocytic pleocytosis, elevated blood erythrocyte sedimentation rate and serum lactate dehydrogenase. Malignant cells are rarely seen in cerebrospinal fluid, blood or bone marrow. Neuroimaging is usually abnormal with parenchymal lesions seen on cerebral tomography and magnetic resonance imaging along with an occasional meningeal pattern of contrast enhancement. Treatment with corticosteroids, chemotherapy, radiation therapy, or plasmapheresis provided limited benefit. Intravascular lymphomatosis should be considered in the differential diagnosis of unexplained progressive encephalopathy with superimposed focal deficits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572046     DOI: 10.1111/j.1600-0404.1995.tb00452.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  21 in total

1.  A 59 year old man with progressive spinal cord and peripheral nerve dysfunction culminating in encephalopathy: Edinburgh advanced clinical neurology course, 1999.

Authors:  R Al-Shahi; C P Warlow; G H Jansen; C J Frijns; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

2.  A case of intravascular lymphoma with increased regional cerebral blood flow in I-123 IMP single-photon emission CT.

Authors:  Chihoko Miyazaki; Masaya Mukai; Yuriko Kawaai; Miki Takeda; Norio Katoh; Syunsuke Nagano; Kozoh Kubo; Michifumi Kohno
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

3.  Intravascular large B-cell lymphoma presenting as an isolated cauda equina-conus medullaris syndrome - A case report.

Authors:  Yang Yu; Raghav Govindarajan
Journal:  J Spinal Cord Med       Date:  2018-10-22       Impact factor: 1.985

4.  Angiotropic large cell lymphoma with imaging characteristics of CNS vasculitis.

Authors:  Debbie K Song; Nicholas M Boulis; Paul E McKeever; Douglas J Quint
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

Review 5.  A new approach to the diagnosis and treatment of intravascular lymphoma.

Authors:  Joachim M Baehring; Janina Longtine; Fred H Hochberg
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

6.  A 52-Year-Old Man With Seizures and Progressive Cerebrovascular Lesions.

Authors:  Christopher M McGraw; Sara C LaHue; Sean Ferris; Andrew W Bollen; Megan B Richie
Journal:  Neurohospitalist       Date:  2020-01-14

7.  Splenic non-Hodgkin's lymphoma without organomegaly: occult presentation with fatal course and post-mortem diagnosis.

Authors:  Russell P Gollard; Diana Garcia
Journal:  Rare Tumors       Date:  2010-03-31

8.  Intravascular lymphomatosis.

Authors:  P C W Lui; G K C Wong; W S Poon; G M K Tse
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 9.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Aissa Haman; Bruce L Miller
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

10.  Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy.

Authors:  Sandra Pekic; Slavica Milicevic; Natasa Colovic; Milica Colovic; Vera Popovic
Journal:  Endocrine       Date:  2008-10-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.